Herkömmliche biochemische Marker, wie Serumeisen, Transferrin oder Ferritin, sind für die Beurteilung des Eisenstatus während der Akut-Phase-Reaktion, z. B. bei entzündlichen Erkrankungen, aber auch in Gegenwart diverser anderer schwerer Erkrankungen, zum Teil so stark gestört, dass eine klinische Interpretation der Messergebnisse schwierig sein kann.
This SEED article is meant to explain the findings focused on cell count and differentiation for pleural, ascitic, cerebrospinal and synovial fluid as well as for CAPD. Traditionally, body fluid counts are performed by manual counting under a microscope using a haemocytometer, but laboratories now have the option of automating their manual processes using automated haematology or urinalysis analysers. This SEED summarises the advantages and disadvantages of haemocytometry and Sysmex analysers and explains briefly the XN-BF mode.
Cerebrospinal fluid as sample material requires particular attention at all times, from sample collection and transport to laboratory diagnostics. Upon arrival at the laboratory, the CSF sample must be processed quickly with great care and expertise so that the analysis results provide the information needed by the physician for treatment decisions. In this article you find a summary of all lab procedures with a focus on cell count and differentiation.
Once the analysis results have been technically validated and considered reliable, they can be looked at from a clinical angle to search for suspect results. The task of biomedical validation is to recognise abnormal or conspicuous quantita¬tive results. Based on the findings compiled by the GFHC, there is a new rule set implemented in Extended IPU looking at things such as cut-off values, assessment of previous values or additional patient information. Check out the recommendation from GFHC.